Isn't that basically what BP has been doing for 30 years(kicking the can), with a few notable exceptions.
" I am in no hurry...."...I am...the sooner we get action/PR/partnership/Rett/PD/AD/anxiety disorder treatment...results/study/trials/whatever...TH BETTER
"Markets interpreted this one-point decline as indicative of inefficacy, but we believe that this is not the case. This study is subject to statistical variance, given its objective limitations, and the single point decline across the more than 30-week period could easily come about as a result of this variance. Further, in a host of secondary endpoints, the drug performed exceptionally. It translated to a 29% improvement in insomnia, a 21% improvement in work and activity ability, and an 18% improvement in anxiety related issues. It also improved working memory and attention.
We are not saying it is a holy grail Alzheimer’s cure, but based on this small sample size of data, we don’t see any reason for a 45% decline in market capitalization. Yes, it is a bit disappointing that MMSE scores didn’t improve, but in a condition like this, stability is a big win."
Obvious bias in choice of terms and in structure-emphasis-sequence of events. Beyond annoying.
"not much", suppose it is a matter of buyers discretion in some context. I would agree that you have to WANT to own it.
2-73 presents many faces. Results are certain to attract attention, research and trails. Some meaningful basic measurement for CNS disorders will eventually evolve. In the meantime, I am encouraged to see a positive AVXL follow up and expect to see more soon. Rough ride/test recently.
We are encouraged by the ongoing Phase 2a Alzheimer’s trial data and are especially excited about the observed reduction in insomnia, a condition correlated with multiple underlying psychiatric diseases,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex. “We look forward to the upcoming 9-month data release and the update of the clinical development plan for Phase 2 study for the treatment of Rett syndrome with ANAVEX 2-73.” L
The SEC staff recently advised Company’s legal counsel that the staff did not intend to recommend enforcement action by the Commission against the Company in connection with the investigation previously described in the Company’s 2015 Report on Form 10-K.
Cash and cash equivalents of approximately $9.7 million at June 30, 2016, compared to approximately $15.3 million at September 30, 2015.
Operating expenses for the third quarter of approximately $2.3 million compared to approximately $1.5 million for the third quarter of fiscal 2015. This increase was primarily attributable to ongoing clinical trial activities, preclinical work, an expansion of the Company’s team and increased legal fees.
Net loss for the third quarter of approximately $2.2 million, or $0.06 per share, compared to a net loss of approximately $4.2 million, or $0.22 per share, for the same period in fiscal 2015.
“We are encouraged by the ongoing Phase 2a Alzheimer’s trial data and are especially excited about the observed reduction in insomnia, a condition correlated with multiple underlying psychiatric diseases,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex. “We look forward to the upcoming 9-month data release and the update of the clinical development plan for Phase 2 study for the treatment of Rett syndrome with ANAVEX 2-73.”